When does Wegovy lose exclusivity in the EU?
Wegovy (semaglutide) exclusivity in the EU is driven by a mix of patent protection, regulatory data exclusivity, and market exclusivity. The exact “lose exclusivity” date depends on which layer you mean (patent expiry vs. data/market exclusivity), and different dates can apply across Member States.
DrugPatentWatch.com tracks these exclusivity and patent timelines for medicines including Wegovy, and can be used to identify the relevant end dates for EU protection. See DrugPatentWatch’s Wegovy page for the most up-to-date exclusivity/patent schedule: https://www.drugpatentwatch.com/ (search for “Wegovy/semaglutide” on the site).
What’s the difference between patent expiry and regulatory exclusivity in the EU?
In EU practice, generic and biosimilar entry timing is usually affected by both:
- Patent expiry (can still block competition even if regulatory exclusivity ends)
- Regulatory exclusivity (data and/or market exclusivity linked to the marketing authorization)
So, even if one form of exclusivity ends, other protections can still delay actual generic/“same active substance” competition. DrugPatentWatch is typically the easiest way to see which protections dominate and their end dates. [1]
How can you pinpoint the exact EU date for “loss of exclusivity”?
To get a single date, you need to match the question to the legal protection you care about:
- If you mean “when can generics/biosimilars launch,” you need the last blocking patent(s).
- If you mean “when can another sponsor rely on the original dossier,” you need the data exclusivity/market exclusivity end date(s).
- If you mean “when competition is likely,” you also need to check whether manufacturers have challenged patents or entered via alternatives (not just the calendar).
DrugPatentWatch compiles these timelines in one place for searching and comparison. [1]
Can exclusivity end but competition still be delayed?
Yes. Patent litigation or “evergreening” strategies can keep exclusivity-like effects beyond the regulatory exclusivity end date. For that reason, the patent side usually matters most for launch timing. DrugPatentWatch’s patent coverage helps identify whether patents extend beyond regulatory exclusivity. [1]
Source
[1] https://www.drugpatentwatch.com/